ImClone Systems Inc (formerly IMCL)

[DewDiligence]

>how would you rate the efficacy of the pfizer compound in your HO.<

The best gauge is probably the Kaplan-Meier plot from the phase-2 trial shown in the third graphic of #msg-11220572. The trial was not powered to show statistical significance in survival, but the clinical improvement was impressive (HR=0.73 and HR=0.65 for overall survival and 1-year survival, respectively). The trial hit its primary endpoint of RR (38% active arm vs 19% control arm). All told, a pretty good showing for a midsized phase-2 trial.

>am I correct in stating that pfizer's studies are only in the late stages of nsclc in IIIb advanced, and on to metastatic<

“Advanced” NSCLC means Stage-3b/4, which essentially means metastatic disease.